Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/17863Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Rivalland, Gareth | - |
| dc.contributor.author | Mitchell, Paul L R | - |
| dc.date | 2016-06-06 | - |
| dc.date.accessioned | 2018-06-18T00:11:20Z | - |
| dc.date.available | 2018-06-18T00:11:20Z | - |
| dc.date.issued | 2016-07 | - |
| dc.identifier.citation | Lancet Oncology 2016; 17(7): 860-862 | - |
| dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/17863 | - |
| dc.language.iso | eng | - |
| dc.title | Combined BRAF and MEK inhibition in BRAF-mutant NSCLC. | - |
| dc.type | Journal Article | - |
| dc.identifier.journaltitle | The Lancet Oncology | - |
| dc.identifier.affiliation | Department of Medical Oncology, Austin Health, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, Victoria, Australia | - |
| dc.identifier.affiliation | University of Melbourne, Victoria, Australia | - |
| dc.identifier.affiliation | Thoracic Alliance for Cancer Trials, Milton, QLD, Australia | - |
| dc.identifier.doi | 10.1016/S1470-2045(16)30203-0 | - |
| dc.identifier.pubmedid | 27283865 | - |
| dc.type.austin | Journal Article | - |
| dc.type.austin | Comment | - |
| local.name.researcher | Mitchell, Paul L R | |
| item.openairetype | Journal Article | - |
| item.cerifentitytype | Publications | - |
| item.grantfulltext | none | - |
| item.fulltext | No Fulltext | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| item.languageiso639-1 | en | - |
| crisitem.author.dept | Medical Oncology | - |
| crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
| Appears in Collections: | Journal articles | |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.